Stergios J Moschos

6PUBLICATIONS
16CO-AUTHORS
Medical biotechnology not elsewhere classifiedPredictive and prognostic markersMolecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 01, 2023
Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma.

Jorge D Oldan, Benjamin C Giglio, Eric Smith

|Feb 24, 2023
Development of [18F]F-5-OMe-Tryptophans through Photoredox Radiofluorination: A New Method to Access Tryptophan-Based PET Agents.

Xuedan Wu, Xinrui Ma, Yaofeng Zhong

|Jan 26, 2023
Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma.

Prashanthi Dharanipragada, Xiao Zhang, Sixue Liu

|May 31, 2022
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.

Stergios J Moschos, Shahneen Sandhu, Karl D Lewis

|May 19, 2022
War against NRAS-Mutant Melanoma Using Targeted Therapies Remains Challenging.

Stergios J Moschos

|May 09, 2022
Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents.

Stergios J Moschos

Pageof 1

Frequent Collaborators

1 joint publications

Prashanthi Dharanipragada

1 joint publications

Xiao Zhang

1 joint publications

Sixue Liu

1 joint publications

Shirley H Lomeli